Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial.
Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial. Journal of the European Academy of Dermatology and Venereology : JEADV Okata-Karigane, U., Pathmarajah, P., Gorell, E. S., Sum, K., Yekrang, K., Phung, M., Barriga, M., Udrizar, P., Bailey, I., Li, S., Lu, Y., Tang, J. Y., Chiou, A. S. 2024View details for DOI 10.1111/jdv.20189
View details for PubMedID 38949042